Catalysts

Catalysts — What Can Move the Stock

The next six months hinge on a single bilateral event: whether Elevance can close the CMS Medicare Advantage compliance window by July 31, 2026 without sanctions, and whether the Q2 2026 print in late July confirms that 86.8% medical loss ratio held. Q1 already gave the bull thesis its first concrete proof point — adjusted EPS $12.58 vs. $10.82 consensus, FY26 guide raised to ≥$26.75, MA on track to 2% margin — but the calendar from here is dense, regulatory, and binary. The bear's primary trigger (Q2 earnings) and the bull's primary catalyst (Q3 earnings) both fall inside the 6-month window, and they sit on either side of a CMS deadline that the last two extensions tell us is not routine.

Catalyst Setup

The calendar is busy and consequential, not thin. Five hard-dated events sit inside the next six months, each connected to a specific bull/bear tension that this run's specialists already named. The Q1 raise reset the framing — investors now own a "trough confirmed" stock at 13x trough EPS — but the credibility of that framing has been broken twice in 18 months, and the next two prints will tell underwriters whether to extrapolate the Q1 inflection into the 2027 EPS bridge of ≥$28.85.

Ranked Catalyst Timeline

The two events that genuinely change underwriting are #1 (CMS deadline) and #2 (Q2). They sit ~9 days apart and they are the same story in two different forms — the deadline is the regulatory expression of the same risk-adjustment data integrity issue that drove the $935M accrual, and the Q2 print is when the cash-conversion-cycle and reserve-adequacy questions raised by the Q1 days-in-claims-payable jump from 41.3 to 46.6 will get their first independent test.

Impact Matrix

The matrix collapses into a simple shape: only two catalysts are pure bull-case fuel (#3, #4); only one is purely bear (#2 in its strict bear-trigger configuration); the other two (#1 RADV, #5 Medicaid rates) are bilateral and resolve the debate either way. Anything that does not appear in this matrix — the May annual meeting, the June Goldman conference, dividend pay dates, insider Form 4s — is calendar context, not decision-grade evidence.

Next 90 Days

The next 90 days (through end-July 2026) contain three hard-dated, high-impact catalysts and one venue event. This is the densest catalyst stretch of the entire 12-month forward calendar, because the CMS deadline and Q2 earnings are stacked.

What Would Change the View

Three observable signals would most change the investment debate over the next six months. First, the CMS RADV resolution outcome — a clean July 31 attestation acceptance with the final settlement disclosed at or below $935M and no prior-period restatement language eliminates the largest single regulatory tail and resolves the forensic question about whether Q1's days-in-claims-payable jump foreshadowed bigger reserve issues; the opposite outcome (sanctions or prior-period implications) validates the bear's "regulatory haircut to MA economics" framing for the entire industry. Second, the Q2 medical loss ratio relative to 87% — a second consecutive sub-88% print with Medicaid tracking the -1.75% guide reopens the path to mid-cycle EPS of $30+ and 5y-mean P/E re-rating; an MLR drift toward 88%+ with deteriorating Medicaid is the explicit bear primary trigger and reactivates the "structurally lower-margin business" thesis priced into the 13.9x multiple. Third, the Medicaid 2027 rate-cycle aggregate disclosure on the Q3 call — does the aggregate state rate update bridge to historical 2.5–3.0% Medicaid op margin? That single data point is the difference between a 2027 EPS bridge of $28.85+ (bull) and $26 (bear), and it sits inside, not beyond, this 6-month window. Beyond these three, the PY2028 Star Ratings release in early October is a meaningful but secondary input — PY2027 economics are already locked in.